2026-04-17T05:37:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1555172025-12-05T14:53:03Zcom_2072_1057col_2072_478917col_2072_478924

00925njm 22002777a 4500 dc Ramírez-Garza, Sonia L. author Laveriano-Santos, Emily P. author Marhuenda-Muñoz, María author Storniolo, Carolina Emilia author Resserra i Rimbau, Anna author Vallverdú i Queralt, Anna author Lamuela Raventós, Rosa Ma. author 2020-04-16T10:18:45Z 2020-04-16T10:18:45Z 2018-12-03 2020-04-16T10:18:45Z The effect of resveratrol (RV) intake has been reviewed in several studies performed in humans with different health status. The purpose of this review is to summarize the results of clinical trials of the last decade, in which RV was determined in biological samples such as human plasma, urine, and feces. The topics covered include RV bioavailability, pharmacokinetics, effects on cardiovascular diseases, cognitive diseases, cancer, type 2 diabetes (T2D), oxidative stress, and inflammation states. The overview of the recent research reveals a clear tendency to identify RV in plasma, showing that its supplementation is safe. Furthermore, RV bioavailability depends on several factors such as dose, associated food matrix, or time of ingestion. Notably, enterohepatic recirculation of RV has been observed, and RV is largely excreted in the urine within the first four hours after consumption. Much of the research on RV in the last 10 years has focused on its effects on pathologies related to oxidative stress, inflammatory biomarkers, T2D, cardiovascular diseases, and neurological diseases Biodisponibilitat Obesitat Trastorns del metabolisme Antioxidants Farmacologia Bioavailability Obesity Disorders of metabolism Antioxidants Pharmacology Health Effects of Resveratrol: Results from Human Intervention Trials